SG10201804139VA - Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde - Google Patents

Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde

Info

Publication number
SG10201804139VA
SG10201804139VA SG10201804139VA SG10201804139VA SG10201804139VA SG 10201804139V A SG10201804139V A SG 10201804139VA SG 10201804139V A SG10201804139V A SG 10201804139VA SG 10201804139V A SG10201804139V A SG 10201804139VA SG 10201804139V A SG10201804139V A SG 10201804139VA
Authority
SG
Singapore
Prior art keywords
free base
pyrazol
benzaldehyde
pyridin
methoxy
Prior art date
Application number
SG10201804139VA
Other languages
English (en)
Inventor
Zhe Li
Stephan D Parent
Travis Houston
Original Assignee
Global Blood Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53774359&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG10201804139V(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Global Blood Therapeutics Inc filed Critical Global Blood Therapeutics Inc
Publication of SG10201804139VA publication Critical patent/SG10201804139VA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
SG10201804139VA 2014-02-07 2015-02-05 Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde SG10201804139VA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461937404P 2014-02-07 2014-02-07
US201461937393P 2014-02-07 2014-02-07

Publications (1)

Publication Number Publication Date
SG10201804139VA true SG10201804139VA (en) 2018-06-28

Family

ID=53774359

Family Applications (4)

Application Number Title Priority Date Filing Date
SG10201804139VA SG10201804139VA (en) 2014-02-07 2015-02-05 Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
SG11201510135XA SG11201510135XA (en) 2014-02-07 2015-02-05 Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
SG10201911668VA SG10201911668VA (en) 2014-02-07 2015-02-05 Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
SG10201911662YA SG10201911662YA (en) 2014-02-07 2015-02-05 Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde

Family Applications After (3)

Application Number Title Priority Date Filing Date
SG11201510135XA SG11201510135XA (en) 2014-02-07 2015-02-05 Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
SG10201911668VA SG10201911668VA (en) 2014-02-07 2015-02-05 Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
SG10201911662YA SG10201911662YA (en) 2014-02-07 2015-02-05 Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde

Country Status (32)

Country Link
US (7) US9447071B2 (enrdf_load_stackoverflow)
EP (2) EP3868745A1 (enrdf_load_stackoverflow)
JP (4) JP6809681B2 (enrdf_load_stackoverflow)
KR (2) KR102345380B1 (enrdf_load_stackoverflow)
CN (4) CN105431147A (enrdf_load_stackoverflow)
AP (1) AP2016009261A0 (enrdf_load_stackoverflow)
AU (3) AU2015214182B2 (enrdf_load_stackoverflow)
BR (1) BR112015032160B1 (enrdf_load_stackoverflow)
CA (1) CA2916564C (enrdf_load_stackoverflow)
CY (1) CY1124097T1 (enrdf_load_stackoverflow)
DK (1) DK3102208T4 (enrdf_load_stackoverflow)
EA (1) EA028529B1 (enrdf_load_stackoverflow)
ES (1) ES2860648T5 (enrdf_load_stackoverflow)
FI (1) FI3102208T4 (enrdf_load_stackoverflow)
HR (1) HRP20210388T4 (enrdf_load_stackoverflow)
HU (1) HUE053706T2 (enrdf_load_stackoverflow)
IL (2) IL243214B (enrdf_load_stackoverflow)
LT (1) LT3102208T (enrdf_load_stackoverflow)
MX (2) MX361810B (enrdf_load_stackoverflow)
MY (1) MY189995A (enrdf_load_stackoverflow)
NZ (1) NZ715029A (enrdf_load_stackoverflow)
PE (2) PE20160179A1 (enrdf_load_stackoverflow)
PL (1) PL3102208T5 (enrdf_load_stackoverflow)
PT (1) PT3102208T (enrdf_load_stackoverflow)
RS (1) RS61653B2 (enrdf_load_stackoverflow)
SA (1) SA516370358B1 (enrdf_load_stackoverflow)
SG (4) SG10201804139VA (enrdf_load_stackoverflow)
SI (1) SI3102208T2 (enrdf_load_stackoverflow)
SM (1) SMT202100160T1 (enrdf_load_stackoverflow)
TW (4) TWI799115B (enrdf_load_stackoverflow)
WO (1) WO2015120133A1 (enrdf_load_stackoverflow)
ZA (1) ZA202401707B (enrdf_load_stackoverflow)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3738434T1 (sl) 2011-12-28 2024-01-31 Global Blood Therapeutics, Inc. Vmesne spojine za pridobivanje substituiranih benzaldehidnih spojin in postopki njihove uporabe pri povečanju oksigenacije tkiv
HK1203412A1 (en) 2011-12-28 2015-10-30 Global Blood Therapeutics, Inc. Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation
EP2968299B1 (en) 2013-03-15 2021-01-20 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
WO2014145040A1 (en) 2013-03-15 2014-09-18 Global Blood Therapeutics, Inc. Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation
US8952171B2 (en) 2013-03-15 2015-02-10 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9422279B2 (en) 2013-03-15 2016-08-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
SG10201802911RA (en) 2013-03-15 2018-05-30 Global Blood Therapeutics Inc Compounds and uses thereof for the modulation of hemoglobin
KR102293060B1 (ko) 2013-03-15 2021-08-23 글로벌 블러드 테라퓨틱스, 인크. 헤모글로빈 조정을 위한 화합물 및 이의 용도
US9458139B2 (en) 2013-03-15 2016-10-04 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US10266551B2 (en) 2013-03-15 2019-04-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
EA202092627A1 (ru) 2013-11-18 2021-09-30 Глобал Блад Терапьютикс, Инк. Соединения и их применения для модуляции гемоглобина
CA2939120A1 (en) 2014-01-10 2015-07-16 Rgenix, Inc. Lxr agonists and uses thereof
KR102345380B1 (ko) * 2014-02-07 2021-12-29 글로벌 블러드 테라퓨틱스, 인크. 2-하이드록시-6-((2-(1-이소프로필-1h-피라졸-5-일)피리딘-3-일)메톡시)벤즈알데하이드의 유리 염기의 결정성 다형체
MA41841A (fr) 2015-03-30 2018-02-06 Global Blood Therapeutics Inc Composés aldéhyde pour le traitement de la fibrose pulmonaire, de l'hypoxie, et de maladies auto-immunes et des tissus conjonctifs
DK3383392T3 (da) 2015-12-04 2025-08-18 Global Blood Therapeutics Inc Doseringsskema for 2.HYDROXY.6.((2.(1.ISOPROPYL.1H.PYRAZOL.5.YL)PYRIDIN.3.YL)METHOXY)BENZALDEHYD
TWI825524B (zh) * 2016-05-12 2023-12-11 美商全球血液治療公司 用於合成2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)-吡啶-3-基)甲氧基)苯甲醛之方法
WO2017218960A1 (en) 2016-06-17 2017-12-21 Fronthera U.S. Pharmaceuticals Llc Hemoglobin modifier compounds and uses thereof
CN106227475A (zh) * 2016-07-18 2016-12-14 重庆市中迪医疗信息科技股份有限公司 打印系统及其方法
TW202332423A (zh) 2016-10-12 2023-08-16 美商全球血液治療公司 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑
JP2021504315A (ja) 2017-11-21 2021-02-15 ルジェニクス，インコーポレーテッド 多形及びその使用
EP3860975B1 (en) 2018-10-01 2023-10-18 Global Blood Therapeutics, Inc. Modulators of hemoglobin for the treatment of sickle cell disease
SMT202200106T1 (it) 2018-11-19 2022-05-12 Global Blood Therapeutics Inc Composti 2-formil-3-idrossifenilossimetilici in grado di modulare l'emoglobina
CN113365992B (zh) * 2018-12-21 2024-05-28 晶体制药独资有限公司 用于沃塞洛托的制备的方法和中间体
EP3693364A1 (en) 2019-02-11 2020-08-12 Sandoz Ag Crystalline salts of a hemoglobin s allosteric modulator
KR102727505B1 (ko) * 2019-09-12 2024-11-06 아심켐 래보러토리즈 (푸신) 컴퍼니, 리미티드 2,6-디히드록시벤즈알데히드의 연속 제조 장치 및 그 응용
IL292982A (en) 2019-11-19 2022-07-01 Global Blood Therapeutics Inc Methods of administering voxelotor
HUE067466T2 (hu) 2019-12-13 2024-10-28 Inspirna Inc Fémsók és alkalmazásuk
GB202002560D0 (en) * 2020-02-24 2020-04-08 Johnson Matthey Plc Crystalline forms of voxelotor, and processes for the preparation thereof
EP3888750A1 (en) 2020-04-02 2021-10-06 Sandoz AG Crystalline form of voxelotor
WO2021224280A1 (en) 2020-05-05 2021-11-11 Dipharma Francis S.R.L. Synthesis of a sickle cell disease agent and intermediates thereof
IT202000009970A1 (it) 2020-05-05 2021-11-05 Dipharma Francis Srl Procedimento per la preparazione di un farmaco per il trattamento dell’anemia falciforme
EP3939589A1 (en) 2020-07-15 2022-01-19 Sandoz Ag High drug load tablet comprising voxelotor
WO2022013052A1 (en) 2020-07-15 2022-01-20 Sandoz Ag Compounds comprising voxelotor and 2,5-dihydroxybenzoic acid and crystal forms
CN112047924B (zh) * 2020-10-10 2023-04-18 山东汇海医药化工有限公司 一种沃克洛多的制备方法
CN116710441A (zh) * 2020-11-06 2023-09-05 全球血液疗法公司 制备2-羟基-6-((2-(1-异丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)苯甲醛的方法
WO2022099064A2 (en) 2020-11-06 2022-05-12 Global Blood Therapeutics, Inc. Process for preparation of 2-hydroxy-6-((2-(1-isopropyl- 1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
EP4261212A4 (en) * 2020-12-10 2024-11-27 Principia Biopharma Inc. CRYSTALLINE FORM OF TOLEBRUTINIB, ITS PREPARATION PROCESS AND ITS USE
US11084780B1 (en) 2021-02-17 2021-08-10 Springworks Therapeutics, Inc. Crystalline solids of MEK inhibitor N-((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and uses thereof
AU2021428512A1 (en) * 2021-02-17 2023-09-21 Springworks Therapeutics, Inc. Crystalline solids of mek inhibitor n-((r)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-benzamide and uses thereof
WO2022249200A1 (en) * 2021-05-25 2022-12-01 Msn Laboratories Private Limited, R&D Center Novel crystalline forms of 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridine-3-yl) methoxy)benzaldehyde
AU2022381755A1 (en) 2021-11-05 2024-05-16 Global Blood Therapeutics, Inc. Methods of treating sickle cell disease with voxelotor
WO2023199345A1 (en) * 2022-04-14 2023-10-19 Msn Laboratories Private Limited, R&D Center Novel solid state forms of voxelotor and their preparation methods thereof
CN115636742B (zh) * 2022-11-11 2024-04-09 江西亚太科技发展有限公司 一种重结晶的方法

Family Cites Families (267)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE554933A (enrdf_load_stackoverflow) 1956-02-13 1900-01-01
BE787580A (fr) 1971-08-13 1973-02-14 Hoechst Ag Procede de preparation de derives du furanne
BE787576A (fr) 1971-08-13 1973-02-14 Hoechst Ag Derives de benzofuranne et leur utilisation comme azureurs optiques
GB1409865A (en) 1973-02-13 1975-10-15 Science Union & Cie Dihydropyridines derivatives their preparation and pharmaceu tical compositions containing them
US4062858A (en) 1976-12-22 1977-12-13 E. R. Squibb & Sons, Inc. Derivatives of 5,6-dihydrobenzo[5,6]cyclohepta[1,2-b]pyrazolo[4,3-e]pyridin-11(1H)-ones and 11(1H)-imines
GB1593417A (en) 1976-12-22 1981-07-15 Squibb & Sons Inc Carbocyclic-fused pyrazolopyridine derivatives
EP0010063B1 (de) 1978-10-04 1982-12-29 Ciba-Geigy Ag Verfahren zur Herstellung von Furanyl-benzazolen
DE2853765A1 (de) 1978-12-13 1980-06-26 Bayer Ag Verfahren zur herstellung von benzimidazolylbenzofuranen
DE2904829A1 (de) 1979-02-08 1980-08-14 Bayer Ag Verfahren zur herstellung von benzimidazolylbenzofuran
ZA803880B (en) 1979-06-29 1982-02-24 Wellcome Found Pharmaceutical ethers,preparation,use and intermediates therefor and their preparation
ZA818741B (en) 1980-12-18 1983-07-27 Wellcome Found Pharmaceutical compounds,preparation,use and intermediates therefor and their preparation
JPS5929667A (ja) 1982-08-13 1984-02-16 Otsuka Pharmaceut Co Ltd カルボスチリル誘導体および強心剤
US4478834A (en) 1983-02-11 1984-10-23 Usv Pharmaceutical Corporation Dihydropyridines and their use in the treatment of asthma
GB8402740D0 (en) 1984-02-02 1984-03-07 Scras Furo-(3 4-c)-pyridine derivatives
JPS6140236A (ja) 1984-08-02 1986-02-26 Yamanouchi Pharmaceut Co Ltd ハイドロキノン誘導体
DE3431004A1 (de) 1984-08-23 1986-03-06 Hoechst Ag, 6230 Frankfurt Neue 3-pyridylverbindungen und verfahren zu ihrer herstellung
DD226590A1 (de) 1984-09-07 1985-08-28 Univ Leipzig Mittel zur phagenhemmung in mikrobiellen produktionsprozessen
GB8603475D0 (en) 1986-02-12 1986-03-19 Glaxo Group Ltd Chemical compounds
DK111387A (da) 1986-03-05 1987-09-06 Otsuka Pharma Co Ltd Carbostyrilderivater og salte deraf, laegemiddel indeholdende saadanne derivater samt fremgangsmaade til fremstilling af derivaterne
US4831041A (en) 1986-11-26 1989-05-16 Fujisawa Pharmaceutical Co., Ltd. Imidazopyridine compounds and processes for preparation thereof
EP0278686A1 (en) 1987-02-07 1988-08-17 The Wellcome Foundation Limited Pyridopyrimidines methods for their preparation and pharmaceutical formulations thereof
DD258226A1 (de) 1987-03-05 1988-07-13 Fahlberg List Veb Verfahren zur herstellung von aroxymethylchinoxalinen
JPH07121937B2 (ja) 1987-03-18 1995-12-25 大塚製薬株式会社 カルボスチリル誘導体
JPS63258463A (ja) 1987-04-14 1988-10-25 Kumiai Chem Ind Co Ltd ２−フエノキシピリミジン誘導体及び除草剤
GB8711802D0 (en) 1987-05-19 1987-06-24 Fujisawa Pharmaceutical Co Dithioacetal compounds
GB8718940D0 (en) 1987-08-11 1987-09-16 Glaxo Group Ltd Chemical compounds
US4920131A (en) 1987-11-03 1990-04-24 Rorer Pharmaceutical Corp. Quinoline derivatives and use thereof as antagonists of leukotriene D4
JP2650038B2 (ja) 1988-01-27 1997-09-03 サントリー株式会社 ピロリチジン化合物およびその用途
JPH01305081A (ja) 1988-04-04 1989-12-08 E R Squibb & Sons Inc ３―アシルアミノ―１―［［［（置換スルホニル）アミノ〕カルボニル〕アミノ〕―２―アゼチジノン類
US4952574A (en) 1988-09-26 1990-08-28 Riker Laboratories, Inc. Antiarrhythmic substituted N-(2-piperidylmethyl)benzamides
IE81170B1 (en) 1988-10-21 2000-05-31 Zeneca Ltd Pyridine derivatives
DD276480A1 (de) 1988-10-26 1990-02-28 Fahlberg List Veb Verfahren zur herstellung von naphtho/2,1-b/fur-2-ylchinoxalinen
DD276479A1 (de) 1988-10-26 1990-02-28 Fahlberg List Veb Verfahren zur herstellung von benzo/b/fur-2-ylchinoxalinen
US5236917A (en) 1989-05-04 1993-08-17 Sterling Winthrop Inc. Saccharin derivatives useful as proteolytic enzyme inhibitors and compositions and method of use thereof
IT1230859B (it) 1989-06-05 1991-11-08 Corvi Camillo Spa 2 alchinilfenoli sostituiti ad azione anti infiammatoria, procedimento per la loro preparazione e composizioni farmaceutiche che li contengono.
EP0453210A3 (en) 1990-04-19 1993-01-13 Imperial Chemical Industries Plc Pyridine derivatives
AU641769B2 (en) 1990-06-18 1993-09-30 Merck & Co., Inc. Inhibitors of HIV reverse transcriptase
CN1034934C (zh) 1990-06-19 1997-05-21 明治制果株式会社 血管紧张素ii拮抗性吡啶衍生物的制备方法
NL9001752A (nl) 1990-08-02 1992-03-02 Cedona Pharm Bv Nieuwe 1,4-dihydropyridinederivaten.
IL99731A0 (en) 1990-10-18 1992-08-18 Merck & Co Inc Hydroxylated pyridine derivatives,their preparation and pharmaceutical compositions containing them
US5403816A (en) 1990-10-25 1995-04-04 Kumiai Chemical Industry Co., Ltd. Picolinic acid derivative and herbicidal composition
JPH05301872A (ja) 1992-04-23 1993-11-16 Kumiai Chem Ind Co Ltd ピコリン酸誘導体及び除草剤
EP0498380A1 (de) 1991-02-08 1992-08-12 Byk Gulden Lomberg Chemische Fabrik Gmbh Komplexbildner
JPH0641118A (ja) 1991-05-31 1994-02-15 Kumiai Chem Ind Co Ltd ピコリン酸誘導体及び除草剤
US5185251A (en) 1991-06-07 1993-02-09 Merck & Co., Inc. Microbial transformation of a substituted pyridinone using actinoplanacete sp. MA 6559
JP2600644B2 (ja) 1991-08-16 1997-04-16 藤沢薬品工業株式会社 チアゾリルベンゾフラン誘導体
FR2680512B1 (fr) 1991-08-20 1995-01-20 Adir Nouveaux derives de 2,4-thiazolidinedione, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
US5202243A (en) 1991-10-04 1993-04-13 Merck & Co., Inc. Method of hydroxylating 3-[2-(benzoxazol-2-yl)ethyl]-5-ethyl-6-methyl-2-(1H)-pyridinone by incubation with liver slices
GB9203798D0 (en) 1992-02-21 1992-04-08 Fujisawa Pharmaceutical Co Quinolylbenzofuran derivatives,processes for preparation thereof and pharmaceutical composition comprising the same
WO1994001406A1 (de) 1992-07-01 1994-01-20 Byk Gulden Lomberg Chemische Fabrik Gmbh Kontrastmittel für die mr diagnostik
US5290941A (en) 1992-10-14 1994-03-01 Merck & Co., Inc. Facile condensation of methylbenzoxazoles with aromatic aldehydes
KR0173145B1 (ko) 1993-04-07 1999-02-01 고바야시 유키오 티아졸리딘 유도체 및 이를 함유하는 약학적 조성물
DE4318550A1 (de) 1993-06-04 1994-12-08 Boehringer Mannheim Gmbh Aryliden-4-oxo-2-thioxo-3- thiazolidincarbonsäuren, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
AU672699B2 (en) 1993-06-30 1996-10-10 Sankyo Company Limited Amide and urea derivatives having anti-hypercholesteremic activity, their preparation and their therapeutic uses
JPH0725882A (ja) 1993-07-07 1995-01-27 Res Dev Corp Of Japan アクロメリン酸ｂおよびｅを製造するための中間体と、その製造方法
ATE180780T1 (de) 1993-08-05 1999-06-15 Hoechst Marion Roussel Inc 2-(piperidin-4-yl, pyridin-4-yl und tetrahydropyridin-4-yl)-benzofuran-7-carbamat derivate, ihre herstellung und verwendung als acetylcholinesterase inhibitoren
EP0640609A1 (en) 1993-08-24 1995-03-01 Ono Pharmaceutical Co., Ltd. Fused phenol derivatives having inhibitory activity on TXA2 synthetase, and 5-lipoxygenase and scavenging activity on oxygen species
US5965566A (en) 1993-10-20 1999-10-12 Enzon, Inc. High molecular weight polymer-based prodrugs
US5880131A (en) 1993-10-20 1999-03-09 Enzon, Inc. High molecular weight polymer-based prodrugs
US5840900A (en) 1993-10-20 1998-11-24 Enzon, Inc. High molecular weight polymer-based prodrugs
US5605976A (en) 1995-05-15 1997-02-25 Enzon, Inc. Method of preparing polyalkylene oxide carboxylic acids
WO1995014015A1 (en) 1993-11-19 1995-05-26 Ciba-Geigy Ag Benzothiophene derivatives possessing a methoxyimino substituent as microbicides
EP0658559A1 (de) 1993-12-14 1995-06-21 Chemisch Pharmazeutische Forschungsgesellschaft m.b.H. Thienothiazinderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als 5-dipoxygenase und Cyclooxygenaseinhibitoren
ATE191485T1 (de) 1994-02-14 2000-04-15 Merrell Pharma Inc Mercaptoacetylamid-1,3,4,5- tetrahydrobenzo(c)azepin-3-ein disulfidderivate als enkephalinase und ace inhibitoren
GB9420557D0 (en) 1994-10-12 1994-11-30 Zeneca Ltd Aromatic compounds
DE4442050A1 (de) 1994-11-25 1996-05-30 Hoechst Ag Heterospiroverbindungen und ihre Verwendung als Elektrolumineszenzmaterialien
US5650408A (en) 1995-06-07 1997-07-22 Karanewsky; Donald S. Thiazolo benzazepine containing dual action inhibitors
TW434240B (en) 1995-06-20 2001-05-16 Zeneca Ltd Aromatic compounds, preparation thereof and pharmaceutical composition comprising same
JP3895404B2 (ja) 1996-05-17 2007-03-22 興和株式会社 カルコン誘導体及びこれを含有する医薬
EP0923580A1 (en) 1996-07-26 1999-06-23 Dr. Reddy's Research Foundation Thiazolidinedione compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions thereof
JP2000516958A (ja) 1996-08-26 2000-12-19 ジェネティックス・インスチチュート・インコーポレーテッド ホスホリパーゼ酵素の阻害剤
US6630496B1 (en) 1996-08-26 2003-10-07 Genetics Institute Llc Inhibitors of phospholipase enzymes
AU4136197A (en) 1996-09-09 1998-03-26 Kyowa Hakko Kogyo Co. Ltd. Pyrrolocarbazole derivatives
KR20000053201A (ko) 1996-11-12 2000-08-25 한스 루돌프 하우스, 헨리테 브룬너, 베아트리체 귄터 제초제로서 유용한 피라졸 유도체
US6043389A (en) 1997-03-11 2000-03-28 Mor Research Applications, Ltd. Hydroxy and ether-containing oxyalkylene esters and uses thereof
US5760232A (en) 1997-06-16 1998-06-02 Schering Corporation Synthesis of intermediates useful in preparing bromo-substituted tricyclic compounds
US6214817B1 (en) 1997-06-20 2001-04-10 Monsanto Company Substituted pyridino pentaazamacrocyle complexes having superoxide dismutase activity
US6011042A (en) 1997-10-10 2000-01-04 Enzon, Inc. Acyl polymeric derivatives of aromatic hydroxyl-containing compounds
US6111107A (en) 1997-11-20 2000-08-29 Enzon, Inc. High yield method for stereoselective acylation of tertiary alcohols
BR9815170A (pt) 1997-12-12 2000-10-10 Euro Celtique S A Luxembourg "método de obter composto aplicável no tratamento de asma em mamìferos"
EP1062216A1 (en) 1998-02-25 2000-12-27 Genetics Institute, Inc. Inhibitors of phospholipase a2
CA2319493A1 (en) 1998-03-18 1999-09-23 Regine Bohacek Heterocyclic signal transduction inhibitors, compositions containing them
US6214879B1 (en) 1998-03-24 2001-04-10 Virginia Commonwealth University Allosteric inhibitors of pyruvate kinase
US6153655A (en) 1998-04-17 2000-11-28 Enzon, Inc. Terminally-branched polymeric linkers and polymeric conjugates containing the same
GB9810860D0 (en) 1998-05-20 1998-07-22 Hoechst Schering Agrevo Gmbh Substituted pyridine and pyrimidines, processes for their preparation and their use as pesticides
US6232320B1 (en) 1998-06-04 2001-05-15 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
TR200100189T2 (tr) 1998-06-04 2001-05-21 Abbott Laboratories Hücre yapışması engelleyici iltihaplanmaya karşı bileşikler
GB9818627D0 (en) 1998-08-26 1998-10-21 Glaxo Group Ltd Improvements in dva vaccination
GB9823871D0 (en) 1998-10-30 1998-12-23 Pharmacia & Upjohn Spa 2-Amino-thiazole derivatives, process for their preparation, and their use as antitumour agents
US20030060425A1 (en) 1998-11-24 2003-03-27 Ahlem Clarence N. Immune modulation method using steroid compounds
RU2198871C1 (ru) 1998-12-14 2003-02-20 Ф.Хоффманн-Ля Рош Аг Фенилглициновые производные
CA2358955A1 (en) 1998-12-31 2000-07-13 Aventis Pharmaceuticals Inc. N-carboxymethyl substituted benzolactams as inhibitors of matrix metalloproteinase
US6544980B2 (en) 1998-12-31 2003-04-08 Aventis Pharmaceuticals Inc. N-carboxymethyl substituted benzolactams as inhibitors of matrix metalloproteinase
BR0009411A (pt) 1999-03-31 2002-01-08 Basf Ag Composto de anilina substituìda, e, processo para a preparação e uso de compostos
US6251927B1 (en) 1999-04-20 2001-06-26 Medinox, Inc. Methods for treatment of sickle cell anemia
MXPA01011502A (es) 1999-05-14 2003-08-20 Boehringer Ingelheim Pharma Compuestos de tipo profarmaco anti-tumorigenos, activados por enzimas.
US6184228B1 (en) 1999-05-25 2001-02-06 Anadys Pharmaceuticals, Inc. Anti-sickling agents: selection methods and effective compounds
HK1045306A1 (zh) 1999-06-03 2002-11-22 Abbott Laboratories 抑制细胞黏附的抗炎化合物
AUPQ105499A0 (en) 1999-06-18 1999-07-08 Biota Scientific Management Pty Ltd Antiviral agents
SK19122001A3 (sk) 1999-06-28 2003-01-09 Janssen Pharmaceutica N. V. Inhibítory replikácie respiračného syncyciálneho vírusu
ATE312100T1 (de) 1999-09-28 2005-12-15 Eisai Co Ltd Chinuclidin-verbindungen und medikamente die diese als aktive wirkstoffe enthalten
CZ20021554A3 (cs) 1999-11-05 2002-10-16 Emisphere Technologies, Inc. Deriváty fenoxykarboxylové sloučeniny a prostředky pro dodávání aktivní sloľky
AUPQ407699A0 (en) 1999-11-16 1999-12-09 Fujisawa Pharmaceutical Co., Ltd. Aminoalcohol derivatives
ATE253561T1 (de) 1999-11-29 2003-11-15 Hoffmann La Roche 2-(3,5-bis-trifluoromethyl-phenyl)-n-methyl-n-( - morpholin-4-yl-4-o-tolyl-pyridin-3-yl)- isobutyramid
AU2930501A (en) 2000-01-07 2001-07-24 Transform Pharmaceuticals, Inc. High-throughput formation, identification, and analysis of diverse solid-forms
AU2001230537A1 (en) 2000-02-01 2001-08-14 Daiichi Pharmaceutical Co., Ltd. Pyridoxazine derivatives
US6506755B2 (en) 2000-02-03 2003-01-14 Hoffmann-La Roche Inc. Thiazolidinecarboxyl acids
AUPQ585000A0 (en) 2000-02-28 2000-03-16 Fujisawa Pharmaceutical Co., Ltd. Aminoalcohol derivatives
AU2001245823A1 (en) 2000-03-17 2001-10-03 Corixa Corporation Novel amphipathic aldehydes and their use as adjuvants and immunoeffectors
AUPQ841300A0 (en) 2000-06-27 2000-07-20 Fujisawa Pharmaceutical Co., Ltd. New aminoalcohol derivatives
AU7061901A (en) 2000-07-14 2002-01-30 Hoffmann La Roche N-oxides as nk1 receptor antagonist prodrugs of 4-phenyl-pyridine derivatives
AU2001281071A1 (en) 2000-08-01 2002-02-13 Gmp Companies, Inc. Ammonium salts of hemoglobin allosteric effectors, and uses thereof
US6653313B2 (en) 2000-08-10 2003-11-25 Warner-Lambert Company Llc 1,4-dihydropyridine compounds as bradykinin antagonists
JP4272338B2 (ja) 2000-09-22 2009-06-03 バイエル アクチェンゲゼルシャフト ピリジン誘導体
AUPR034000A0 (en) 2000-09-25 2000-10-19 Fujisawa Pharmaceutical Co., Ltd. Aminoalcohol derivatives
PL361690A1 (en) 2000-11-20 2004-10-04 Biovitrum Ab Piperazinylpyrazine compounds as agonist or antagonist of serotonin 5ht-2 receptor
WO2002051849A1 (fr) 2000-12-26 2002-07-04 Daiichi Pharmaceutical Co., Ltd. Inhibiteurs cdk4
WO2002053547A1 (fr) 2000-12-28 2002-07-11 Takeda Chemical Industries, Ltd. Derives d'acide alcanoique, procede de production et utilisation correspondants
GB0102595D0 (en) 2001-02-01 2001-03-21 Virk Kuldip Smart solar
US20030022923A1 (en) 2001-03-01 2003-01-30 Medinox, Inc. Methods for treatment of sickle cell anemia
US6627646B2 (en) * 2001-07-17 2003-09-30 Sepracor Inc. Norastemizole polymorphs
AU2002319677B8 (en) 2001-07-23 2009-04-30 Atwater Management Llc Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods
JP2003075970A (ja) 2001-08-31 2003-03-12 Konica Corp ハロゲン化銀カラー写真感光材料、カラー写真感光材料、その画像形成方法及びデジタル画像情報作製方法
KR100467313B1 (ko) 2001-11-22 2005-01-24 한국전자통신연구원 적색 유기 전기발광 화합물 및 그 제조 방법과 전기발광소자
GB0128499D0 (en) 2001-11-28 2002-01-23 Merck Sharp & Dohme Therapeutic agents
US20030187026A1 (en) 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
CA2470931A1 (en) 2001-12-19 2003-07-03 Atherogenics, Inc. Chalcone derivatives and their use to treat diseases
US20030190333A1 (en) 2002-02-04 2003-10-09 Corixa Corporation Immunostimulant compositions comprising aminoalkyl glucosaminide phosphates and saponins
WO2003088980A1 (en) 2002-04-18 2003-10-30 Embury Stephen H Method and composition for preventing pain in sickle cell patients
US6608076B1 (en) 2002-05-16 2003-08-19 Enzon, Inc. Camptothecin derivatives and polymeric conjugates thereof
GB0212785D0 (en) 2002-05-31 2002-07-10 Glaxo Group Ltd Compounds
EP1546137A1 (en) 2002-08-08 2005-06-29 SmithKline Beecham Corporation Benzimidazol-1-yl-thiophene compounds for the treatment of cancer
US7560558B2 (en) 2002-08-23 2009-07-14 Kirin Beer Kabushiki Kaisha Compound having TGFβ inhibitory activity and medicinal composition containing the same
EP1541564A1 (en) 2002-09-10 2005-06-15 Takeda Pharmaceutical Company Limited Five-membered heterocyclic compounds
ATE527238T1 (de) 2002-12-04 2011-10-15 Univ Virginia Commonwealth Mittel mit wirkung gegen sichelzellenanämie
AU2003303239A1 (en) 2002-12-19 2004-07-14 Atherogenics, Inc. Process of making chalcone derivatives
AU2003289440A1 (en) 2002-12-25 2004-07-22 Kissei Pharmaceutical Co., Ltd. Nitrogen-containing heterocycic derivatives, medicinal compositions containing the same and medicinal use thereof
WO2004073675A1 (de) 2003-02-24 2004-09-02 Randolph Riemschneider Kosmetische zusammensetzung mit whitening-effekt, verfahren zu ihrer herstellung und ihre verwendung
US20040186077A1 (en) 2003-03-17 2004-09-23 Medicure International Inc. Novel heteroaryl phosphonates as cardioprotective agents
ZA200507752B (en) 2003-03-28 2007-01-31 Threshold Pharmaceuticals Inc Compositions and methods for treating cancer
WO2004091518A2 (en) 2003-04-11 2004-10-28 Anormed Inc. Cxcr4 chemokine receptor binding compounds
JP2006527210A (ja) 2003-06-12 2006-11-30 ノボ　ノルディスク　アクティーゼルスカブ ホルモン感受性リパーゼ阻害剤としてのピリジニルカルバメート
WO2005019220A2 (en) 2003-08-11 2005-03-03 Cellular Genomics Inc. Substituted imidazo[1,2-a]pyrazines as modulators of kinase activity
US7411083B2 (en) 2003-09-25 2008-08-12 Wyeth Substituted acetic acid derivatives
EP1682508A1 (en) 2003-11-05 2006-07-26 F. Hoffmann-La Roche Ag Phenyl derivatives as ppar agonists
JP2007513082A (ja) 2003-11-10 2007-05-24 シエーリング アクチエンゲゼルシャフト Ｃｃｒ−５アンタゴニストとして有用なベンジルエーテルアミン化合物
AU2004296765B2 (en) 2003-12-02 2011-03-24 Celgene Corporation Methods and compositions for the treatment and management of hemoglobinopathy and anemia
US7378439B2 (en) 2004-01-20 2008-05-27 Usv, Ltd. Process for the preparation of 4-(2-dipropylaminoethyl)-1,3-dihydro-2H-indol-2-one hydrochloride
US20070155744A1 (en) 2004-01-30 2007-07-05 Istituto Di Ricerche Di Biologia Molecolare P, Angeletti S.P.A. N-benzyl-3,4-dihyroxypyridine-2-carboxamide and n-benzyl-2,3-dihydroxypyridine-4- carboxamide compounds useful as hiv integrase inhibitors
GB0403038D0 (en) 2004-02-11 2004-03-17 Novartis Ag Organic compounds
US20070161639A1 (en) 2004-03-09 2007-07-12 Philip Jones Hiv integrase inhibitors
US20080132458A1 (en) 2004-03-10 2008-06-05 Threshold Pharmaceuticals, Inc. Hypoxia-Activated Anti-Cancer Agents
DE102004015226B3 (de) 2004-03-24 2005-08-25 Siemens Ag Verfahren zum Plasmareinigen eines Werkstücks und zu dessen Durchführung geeignete Vorrichtung
EP1745012A4 (en) 2004-04-22 2010-11-03 Univ Virginia Commonwealth COMPOSITIONS OF ALLOSTERIC HEMOGLOBIN MODIFYING SUBSTANCES AND METHOD FOR THE PRODUCTION THEREOF
WO2006003923A1 (ja) 2004-06-30 2006-01-12 Sankyo Company, Limited 置換ベンゼン化合物
TW200606129A (en) 2004-07-26 2006-02-16 Chugai Pharmaceutical Co Ltd Novel cyclohexane derivative, its prodrug, its salt and diabetic therapeutic agent containing the same
GB0420722D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
CA2585165A1 (en) 2004-10-28 2006-05-18 Medicure International Inc. Dual antiplatelet/anticoagulant pyridoxine analogs
EP1831170A4 (en) 2004-12-14 2009-10-14 Astrazeneca Ab SUBSTITUTED AMINOPYRIDINES AND THEIR USE
US7968574B2 (en) 2004-12-28 2011-06-28 Kinex Pharmaceuticals, Llc Biaryl compositions and methods for modulating a kinase cascade
US7858788B2 (en) 2005-02-21 2010-12-28 Shionogi & Co., Ltd. Bicyclic carbamoylpyridone derivative having HIV integrase inhibitory activity
CA2601871A1 (en) 2005-03-19 2006-09-28 Amorepacific Corporation Novel compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and pharmaceutical compositions containing the same
US7829585B2 (en) 2005-03-30 2010-11-09 Eisai R&D Management Co., Ltd. Antifungal agent containing pyridine derivative
GB0506677D0 (en) 2005-04-01 2005-05-11 Btg Int Ltd Iron modulators
SI3372281T1 (sl) 2005-04-28 2021-11-30 Viiv Healthcare Company Policiklični karbamoilpiridonski derivati, ki imajo aktivnost inhibitorja HIV integraze
DE102005025989A1 (de) 2005-06-07 2007-01-11 Bayer Cropscience Ag Carboxamide
JP2006342115A (ja) 2005-06-10 2006-12-21 Shionogi & Co Ltd Ｈｉｖインテグラーゼ阻害活性を有する多環性化合物
MX2007016508A (es) 2005-06-30 2008-03-04 Prosidion Ltd Agonistas del receptor acoplado a la proteina g.
CN100562514C (zh) 2005-07-22 2009-11-25 中国科学院上海药物研究所 一类取代丙酰胺衍生物、其制备方法和用途
GB0516270D0 (en) 2005-08-08 2005-09-14 Glaxo Group Ltd Novel compounds
PL1945622T3 (pl) 2005-10-11 2012-06-29 Univ Pittsburgh Commonwealth Sys Higher Education Izotopowo znaczone związki benzofuranu jako środki obrazujące białka amyloidogenne
EA200801144A1 (ru) 2005-10-27 2008-10-30 Сионоги Энд Ко., Лтд. Полициклическое карбамоилпиридоновое производное, обладающее ингибиторной активностью в отношении интегразы вич
WO2007061923A2 (en) 2005-11-18 2007-05-31 Takeda San Diego, Inc. Glucokinase activators
EP1976851A2 (en) 2006-01-17 2008-10-08 Neurocrine Biosciences, Inc. Phenoxy-substituted pyrimidines as adenosine receptor antagonists
WO2007095495A2 (en) 2006-02-13 2007-08-23 Pharmacopeia, Inc. Benzodiazepine gcnf modulators for stem cell modulation
RU2318818C1 (ru) 2006-04-12 2008-03-10 Общество С Ограниченной Ответственностью "Исследовательский Институт Химического Разнообразия" Азагетероциклы, комбинаторная библиотека, фокусированная библиотека, фармацевтическая композиция и способ получения (варианты)
GB0614586D0 (en) 2006-07-22 2006-08-30 Pliva Istrazivacki Inst D O O Pharmaceutical Formulation
CN101113148A (zh) 2006-07-26 2008-01-30 中国海洋大学 二氧哌嗪类化合物及其制备方法和用途
JP5254228B2 (ja) 2006-07-27 2013-08-07 株式會社アモーレパシフィック バニロイド受容体アンタゴニストとしての、新規化合物、その異性体またはその薬学的に許容される塩；並びにそれを含む医薬組成物
TW200817424A (en) 2006-08-04 2008-04-16 Daiichi Sankyo Co Ltd Benzylphenyl glucopyranoside derivatives
TWI389895B (zh) 2006-08-21 2013-03-21 Infinity Discovery Inc 抑制ｂｃｌ蛋白質與結合夥伴間之交互作用的化合物及方法
ES2670407T3 (es) 2006-09-03 2018-05-30 Techfields Biochem Co. Ltd Profármacos de acetaminofén solubles en agua cargados positivamente y compuestos relacionados con una tasa de penetración de la piel muy rápida
MX2009003673A (es) 2006-10-04 2009-04-22 Pfizer Prod Inc Derivados de piridido[4,3-d]pirimidin-4(3h)-ona como antagonistas de los receptores de calcio.
CN101528707B (zh) 2006-10-23 2012-11-07 默沙东公司 用作糖皮质激素受体配体的2-[1-苯基-5-羟基或甲氧基-4α-甲基-六氢环戊二烯并[f]吲唑-5-基]乙基苯基衍生物
FR2909379B1 (fr) 2006-11-30 2009-01-16 Servier Lab Nouveaux derives heterocycliques,leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
CN101558038B (zh) 2006-11-30 2013-05-01 国立大学法人东京工业大学 姜黄素衍生物
TW200835687A (en) 2006-11-30 2008-09-01 R Tech Ueno Ltd Thiazole derivatives and their use as VAP-1 inhibitor
JP2010519267A (ja) 2007-02-22 2010-06-03 シンジェンタ パーティシペーションズ アクチェンゲゼルシャフト 新規殺微生物剤
TWI407960B (zh) 2007-03-23 2013-09-11 Jerini Ag 小分子緩激肽ｂ２受體調節劑
EP2149545B1 (en) 2007-05-22 2016-10-05 Sumitomo Chemical Company, Limited Method for producing benzaldehyde compound
WO2009001214A2 (en) 2007-06-28 2008-12-31 Pfizer Products Inc. Thieno[2,3-d]pyrimidin-4(3h)-one, isoxazolo[5,4-d]pyrimidin-4(5h)-one and isothiazolo[5,4-d]pyrimidin-4(5h)-one derivatives as calcium receptor antagonists
US20090069288A1 (en) 2007-07-16 2009-03-12 Breinlinger Eric C Novel therapeutic compounds
EP2178845B1 (en) 2007-07-17 2013-06-19 F. Hoffmann-La Roche AG Inhibitors of 11b-hydroxysteroid dehydrogenase
KR101150581B1 (ko) 2007-07-26 2012-06-11 노파르티스 아게 유기 화합물
TW200918521A (en) 2007-08-31 2009-05-01 Astrazeneca Ab Heterocyclic amides and methods of use thereof
WO2009050183A2 (en) 2007-10-17 2009-04-23 Novartis Ag Imidazo [1, 2-a] pyridine derivatives useful as alk inhibitors
AU2008333326B2 (en) 2007-12-04 2013-05-30 F. Hoffmann-La Roche Ag Isoxazolo-pyridine derivatives
US7776875B2 (en) 2007-12-19 2010-08-17 Hoffman-La Roche Inc. Spiroindolinone derivatives
JP2009203230A (ja) 2008-01-31 2009-09-10 Daiichi Sankyo Co Ltd ベンジルフェニルグルコピラノシド誘導体を含有する医薬組成物
KR101586104B1 (ko) 2008-02-14 2016-01-15 스미또모 가가꾸 가부시끼가이샤 벤즈알데히드 화합물의 제조 방법
US8268834B2 (en) * 2008-03-19 2012-09-18 Novartis Ag Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme
AU2009234899A1 (en) 2008-04-11 2009-10-15 Institute Of Medicinal Molecular Design, Inc. PAI-1 inhibitor
US8633245B2 (en) 2008-04-11 2014-01-21 Institute Of Medicinal Molecular Design, Inc. PAI-1 inhibitor
JP2011136906A (ja) 2008-04-18 2011-07-14 Otsuka Pharmaceut Co Ltd 複素環化合物
US8119647B2 (en) 2008-04-23 2012-02-21 Glenmark Pharmaceuticals S.A. Fused pyrimidineone compounds as TRPV3 modulators
WO2009136889A1 (en) 2008-05-08 2009-11-12 Nova Southeastern University Specific inhibitors for vascular endothelial growth factor receptors
CN102112447B (zh) 2008-06-04 2013-06-26 阿姆布里利亚生物制药公司 来自吡哆醇的hiv整合酶抑制剂
DE102008027574A1 (de) 2008-06-10 2009-12-17 Merck Patent Gmbh Neue Pyrrolidinderivate als MetAP-2 Inhibitoren
JP5314330B2 (ja) 2008-06-16 2013-10-16 住友化学株式会社 ２−（アリールオキシメチル）ベンズアルデヒドの製造方法およびその中間体
GB0811451D0 (en) 2008-06-20 2008-07-30 Syngenta Participations Ag Novel microbiocides
AR073304A1 (es) 2008-09-22 2010-10-28 Jerini Ag Moduladores del receptor de bradiquinina b2 de molecula pequena
EP2358716B1 (en) 2008-11-12 2016-01-06 Merck Sharp & Dohme Corp. Inhibitors of fatty acid binding protein (fabp)
TW201033201A (en) 2009-02-19 2010-09-16 Hoffmann La Roche Isoxazole-isoxazole and isoxazole-isothiazole derivatives
HUE033494T2 (en) 2009-03-31 2017-12-28 Ligand Pharm Inc Biphenylsulfonamide Endothelin and Angiotensin II Receptor Antagonist for Glomerulosclerosis
EP2427190B1 (en) 2009-05-08 2013-09-18 Tetraphase Pharmaceuticals, Inc. 8-aza tetracycline compounds
US8486965B2 (en) 2009-08-26 2013-07-16 Takeda Pharmaceutical Company Limited Pyrrolo[2,3-b]pyridine derivative and use thereof for treatment of cancer
WO2011025006A1 (ja) 2009-08-31 2011-03-03 日本ケミファ株式会社 Ｇｐｒ１１９作動薬
WO2011033045A1 (en) 2009-09-21 2011-03-24 F. Hoffmann-La Roche Ag Heterocyclic antiviral compounds
NZ599763A (en) 2009-11-09 2014-06-27 Wyeth Llc Tablet formulations of neratinib maleate
TW201139406A (en) 2010-01-14 2011-11-16 Glaxo Group Ltd Voltage-gated sodium channel blockers
KR101698153B1 (ko) 2010-04-26 2017-01-23 광주과학기술원 Ｐ2ｘ1 및 ｐ2ｘ3 수용체 길항제로 사용되는 신규한 피리딘 카르복실산계 화합물, 이의 제조방법 및 이를 포함하는 조성물
CN102232949A (zh) 2010-04-27 2011-11-09 孙远 提高药物溶出度的组合物及其制备方法
TWI535442B (zh) 2010-05-10 2016-06-01 Kyowa Hakko Kirin Co Ltd A nitrogen-containing heterocyclic compound having an action of inhibiting the production of canine erythritine
MX2012014386A (es) * 2010-06-09 2013-05-01 Abbvie Inc Formas cristalinas de inhibidores de cinasa.
US20120122928A1 (en) 2010-08-11 2012-05-17 Bayer Cropscience Ag Heteroarylpiperidine and -Piperazine Derivatives as Fungicides
CN102116772B (zh) 2010-09-28 2013-08-28 上海大学 二氢查尔酮化合物的筛选方法
CA2823166C (en) 2010-12-27 2019-04-09 Takeda Pharmaceutical Company Limited Orally disintegrating tablet
EP2694514A2 (en) 2011-04-06 2014-02-12 Teva Pharmaceutical Industries Ltd. New intermediates and processes for preparing ticagrelor
US9399635B2 (en) 2011-04-11 2016-07-26 Green Tech Co., Ltd. Pyrazole derivative
CN102952062B (zh) 2011-08-12 2016-06-08 中国医学科学院医药生物技术研究所 取代苯并杂环类化合物及其制备方法和应用
MX2014001933A (es) * 2011-09-15 2014-03-27 Demerx Inc Ansolvatos de sal de noribogaina.
US20140308260A1 (en) 2011-10-07 2014-10-16 Radiorx, Inc. Methods and compositions comprising a nitrite-reductase promoter for treatment of medical disorders and preservation of blood products
HK1203412A1 (en) 2011-12-28 2015-10-30 Global Blood Therapeutics, Inc. Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation
SI3738434T1 (sl) 2011-12-28 2024-01-31 Global Blood Therapeutics, Inc. Vmesne spojine za pridobivanje substituiranih benzaldehidnih spojin in postopki njihove uporabe pri povečanju oksigenacije tkiv
BR112015015216B1 (pt) 2012-12-27 2020-01-07 Sumitomo Chemical Company, Limited Composto de tetrazolinona, agente e método de controle de peste
US8952171B2 (en) 2013-03-15 2015-02-10 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
CA2902874C (en) 2013-03-15 2021-04-20 Global Blood Therapeutics, Inc. Substituted pyridinyl-6-methoxy-benzaldehyde derivatives and pharmaceutical compositions thereof useful for the modulation of hemoglobin
US9458139B2 (en) 2013-03-15 2016-10-04 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US10266551B2 (en) 2013-03-15 2019-04-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
EP2968299B1 (en) 2013-03-15 2021-01-20 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US20140271591A1 (en) 2013-03-15 2014-09-18 Global Blood Therapeutics, Inc. Compositions and methods for the modulation of hemoglobin (s)
WO2014150289A1 (en) 2013-03-15 2014-09-25 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US20150057251A1 (en) 2013-08-26 2015-02-26 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9802900B2 (en) 2013-03-15 2017-10-31 Global Blood Therapeutics, Inc. Bicyclic heteroaryl compounds and uses thereof for the modulation of hemoglobin
WO2014150256A1 (en) 2013-03-15 2014-09-25 Global Blood Therapeutics, Inc. Compositions and methods for the modulation of hemoglobin (s)
SG10201802911RA (en) 2013-03-15 2018-05-30 Global Blood Therapeutics Inc Compounds and uses thereof for the modulation of hemoglobin
KR102293060B1 (ko) 2013-03-15 2021-08-23 글로벌 블러드 테라퓨틱스, 인크. 헤모글로빈 조정을 위한 화합물 및 이의 용도
US9422279B2 (en) 2013-03-15 2016-08-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
WO2014145040A1 (en) 2013-03-15 2014-09-18 Global Blood Therapeutics, Inc. Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation
US9604999B2 (en) 2013-03-15 2017-03-28 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US20140274961A1 (en) 2013-03-15 2014-09-18 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
WO2015031284A1 (en) 2013-08-26 2015-03-05 Global Blood Therapeutics, Inc. Formulations comprising wetting agents and compounds for the modulation of hemoglobin (s)
US20160207904A1 (en) 2013-08-27 2016-07-21 Global Blood Therapeutics, Inc. Crystalline 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde ansolvate salts
WO2015031285A1 (en) 2013-08-27 2015-03-05 Global Blood Therapeutics, Inc. Crystalline 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde ansolvate salts
EA202092627A1 (ru) 2013-11-18 2021-09-30 Глобал Блад Терапьютикс, Инк. Соединения и их применения для модуляции гемоглобина
US20150141465A1 (en) 2013-11-18 2015-05-21 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
WO2015116061A1 (en) 2014-01-29 2015-08-06 Global Blood Therapeutics, Inc. 1:1 adducts of sickle hemoglobin
US9248199B2 (en) 2014-01-29 2016-02-02 Global Blood Therapeutics, Inc. 1:1 adducts of sickle hemoglobin
KR102345380B1 (ko) * 2014-02-07 2021-12-29 글로벌 블러드 테라퓨틱스, 인크. 2-하이드록시-6-((2-(1-이소프로필-1h-피라졸-5-일)피리딘-3-일)메톡시)벤즈알데하이드의 유리 염기의 결정성 다형체
WO2016043849A2 (en) 2014-07-24 2016-03-24 Global Blood Therapeutics, Inc. Compounds for treating acute respiratory distress syndrome or a negative effect thereof
TWI544395B (zh) 2014-09-26 2016-08-01 義隆電子股份有限公司 單層電容式觸控面板之掃描方法及裝置
MA41841A (fr) 2015-03-30 2018-02-06 Global Blood Therapeutics Inc Composés aldéhyde pour le traitement de la fibrose pulmonaire, de l'hypoxie, et de maladies auto-immunes et des tissus conjonctifs
DK3383392T3 (da) 2015-12-04 2025-08-18 Global Blood Therapeutics Inc Doseringsskema for 2.HYDROXY.6.((2.(1.ISOPROPYL.1H.PYRAZOL.5.YL)PYRIDIN.3.YL)METHOXY)BENZALDEHYD
TWI825524B (zh) 2016-05-12 2023-12-11 美商全球血液治療公司 用於合成2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)-吡啶-3-基)甲氧基)苯甲醛之方法
TW202332423A (zh) 2016-10-12 2023-08-16 美商全球血液治療公司 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑
EP3860975B1 (en) 2018-10-01 2023-10-18 Global Blood Therapeutics, Inc. Modulators of hemoglobin for the treatment of sickle cell disease
SMT202200106T1 (it) 2018-11-19 2022-05-12 Global Blood Therapeutics Inc Composti 2-formil-3-idrossifenilossimetilici in grado di modulare l'emoglobina

Also Published As

Publication number Publication date
US20150225366A1 (en) 2015-08-13
MX2015017614A (es) 2016-04-07
PE20201444A1 (es) 2020-12-10
KR102345380B1 (ko) 2021-12-29
IL243214B (en) 2021-09-30
AP2016009261A0 (en) 2016-06-30
AU2015214182B2 (en) 2020-04-30
CY1124097T1 (el) 2022-05-27
EP3102208B2 (en) 2024-07-17
EA201592212A1 (ru) 2016-05-31
ZA202401707B (en) 2025-04-30
JP2023016994A (ja) 2023-02-02
SG10201911662YA (en) 2020-02-27
JP6809681B2 (ja) 2021-01-06
SG11201510135XA (en) 2016-01-28
CA2916564A1 (en) 2015-08-13
IL285918A (en) 2021-10-31
SMT202100160T1 (it) 2021-05-07
SI3102208T1 (sl) 2021-07-30
HRP20210388T1 (hr) 2021-04-16
PT3102208T (pt) 2021-04-05
EA201592212A8 (ru) 2016-07-29
CN114181195A (zh) 2022-03-15
TWI755952B (zh) 2022-02-21
TW202003489A (zh) 2020-01-16
US20210161876A1 (en) 2021-06-03
FI3102208T4 (fi) 2024-09-23
AU2022203213B2 (en) 2024-05-09
PE20160179A1 (es) 2016-05-20
HUE053706T2 (hu) 2021-07-28
MY189995A (en) 2022-03-22
BR112015032160A2 (pt) 2017-07-25
PL3102208T3 (pl) 2021-07-19
DK3102208T4 (da) 2024-08-26
MX2022007912A (es) 2022-07-21
US11452720B2 (en) 2022-09-27
US20160346263A1 (en) 2016-12-01
IL243214A0 (en) 2016-02-29
CN105431147A (zh) 2016-03-23
SG10201911668VA (en) 2020-01-30
EP3102208B1 (en) 2021-01-13
KR20220002722A (ko) 2022-01-06
LT3102208T (lt) 2021-05-10
MX361810B (es) 2018-12-14
ES2860648T3 (es) 2021-10-05
JP2019137699A (ja) 2019-08-22
DK3102208T3 (da) 2021-03-08
AU2020207778B2 (en) 2022-02-17
US20180289686A1 (en) 2018-10-11
JP2017505347A (ja) 2017-02-16
WO2015120133A1 (en) 2015-08-13
BR112015032160B1 (pt) 2021-11-30
JP7444957B2 (ja) 2024-03-06
TWI714182B (zh) 2020-12-21
EP3102208A1 (en) 2016-12-14
KR20160118204A (ko) 2016-10-11
US20190255031A1 (en) 2019-08-22
ES2860648T5 (es) 2024-11-27
EP3102208A4 (en) 2017-06-14
US9447071B2 (en) 2016-09-20
PL3102208T5 (pl) 2024-10-14
EA028529B1 (ru) 2017-11-30
US20250032471A1 (en) 2025-01-30
TW202245761A (zh) 2022-12-01
NZ715029A (en) 2021-07-30
RS61653B1 (sr) 2021-04-29
HRP20210388T4 (hr) 2024-10-11
TW201612171A (en) 2016-04-01
TW202134227A (zh) 2021-09-16
JP2021113225A (ja) 2021-08-05
SI3102208T2 (sl) 2024-10-30
CN114213390A (zh) 2022-03-22
TWI670265B (zh) 2019-09-01
AU2015214182A1 (en) 2016-01-21
SA516370358B1 (ar) 2017-12-21
US20220395492A1 (en) 2022-12-15
KR102588476B1 (ko) 2023-10-11
TWI799115B (zh) 2023-04-11
EP3868745A1 (en) 2021-08-25
US10137118B2 (en) 2018-11-27
AU2020207778A1 (en) 2020-08-06
CN114181194A (zh) 2022-03-15
US10722502B2 (en) 2020-07-28
AU2022203213A1 (en) 2022-06-02
RS61653B2 (sr) 2024-10-31
BR112015032160A8 (pt) 2020-01-14
CA2916564C (en) 2023-02-28

Similar Documents

Publication Publication Date Title
ZA202401707B (en) Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
GB201910389D0 (en) Novel compounds, methods for their manufacture, and uses thereof
TN2016000270A1 (en) Heteroaryls and uses thereof.
MA39749A (fr) Dérivés de pipéridine-dione
ZA201906079B (en) Novel ester compounds, method for the production thereof and use thereof
SG11202103781TA (en) Products, uses & methods
IL271399A (en) Methods for the preparation of heterocyclic 3,1-benzodioxole compounds
ZA201905065B (en) Novel ester compounds, method for the production thereof and use thereof
IL259617B (en) Methods for the preparation of 3,1-benzodioxole heterocyclic compounds
EP3325608A4 (en) METHODS AND MICROORGANISMS FOR PRODUCING 1,3-BUTANEDIOL
ZA201608442B (en) Methods for the preparation of 1,3-benzodioxole heterocyclic compounds
EP3309138A4 (en) Method for co-production of 2,3,3,3-tetrafluoropropylene and 1,3,3,3-tetrafluoropropylene
JOP20190163B1 (ar) منشط nrf2
SG10201908248PA (en) Processes for preparing fluoroketolides
IN2013MU00665A (enrdf_load_stackoverflow)
EP3356514C0 (fr) Nouvelles souches bacteriennes pour la production de vanilline
GEP20207127B (en) 2-homopiperazine-1-yl-4h-1,3-benzothiazine-4-one derivatives and process for the preparation of 2-(homo)piperazine 1,3-benzothiazine-4-one hydrochlorides
JO3562B1 (ar) اشكال بلورية متعدة من القاعدة الحرة من 2-هيدروكسي-6-((2-(1-أيزوبروبيل-1h-بيرازول-5-يل)بيريدين-3-يل)ميثوكسي) بنزالديهيد
PL3347309T3 (pl) Sposoby wytwarzania soli srebra(ii) i ich hydratów, produkty otrzymane tymi sposobami i ich zastosowanie do modyfikacji struktury cząsteczek związków organicznych
HK40113576A (en) Methods for the preparation of 1,3-benzodioxole heterocyclic compounds
EA201791587A1 (ru) Кристаллические полиморфные формы свободного основания 2-гидрокси-6-((2-(1-изопропил-1н-пиразол-5-ил)пиридин-3-ил)метокси)бензальдегида
IN2013MU02010A (enrdf_load_stackoverflow)
GB201817509D0 (en) Products, uses & methods
GB201816700D0 (en) Products, uses & methods
HUP1500451A2 (en) Processes for the preparation of 1,4,7-triaza-cyclononane derivatives and intermediates